Acute hepatic failure following transcatheter arterial embolization for the treatment of hepatocellular carcinoma.
We conducted a retrospective analysis to evaluate the risk factors associated with the occurrence of acute hepatic failure following transcatheter arterial embolization (TAE) for hepatocellular carcinoma. From 1984 to 1993 we performed a total of 623 embolization procedures in 369 patients with both hepatocellular carcinoma and chronic liver disease. Within 2 weeks after TAE, 13 patients (2.1%) experienced hepatic failure as characterized by a rapid increase in serum bilirubin levels and the development of hepatic encephalopathy of grade 2 or higher. These results indicated that the following are risk factors for acute hepatic failure after TAE: poor hepatic functional reserve; high-dose infusion of chemotherapeutic agents, and a history of multiple embolization procedures.
Katsushima
S
S
First Department of Internal Medicine, Osaka Teishin Hospital, Tennouji-ku, Japan.
Inokuma
T
T
Oi
H
H
Okamura
J
J
Higashi
T
T
Takeuchi
R
R
Hidaka
A
A
Shigeno
C
C
Iida
Y
Y
Konishi
J
J
D058186:Acute Kidney Injury / Q000209:etiology / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001663:Bilirubin / Q000097:blood / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D004317:Doxorubicin / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D017114:Liver Failure, Acute / Q000150:complications* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011517:Prothrombin Time; D011655:Pulmonary Embolism / Q000209:etiology / Q000401:mortality; D012307:Risk Factors; D012709:Serum Albumin / Q000378:metabolism
D012709:Serum Albumin; D004317:Doxorubicin; D001663:Bilirubin